View Older Stories View More Recent Stories

Nov 8, 2022 04:02PM ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
Nov 8, 2022 04:02PM ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
Nov 7, 2022 08:00AM Avilar Therapeutics Presents New In Vivo Non-Human Primate Data for ASGPR-Targeting Chimeras (ATACs) at the Keystone Symposium on Targeted Protein Degradation
Nov 4, 2022 08:05AM Ocelot Bio Presents Phase 1 Data Highlighting Activity and Safety of OCE-205 at AASLD The Liver Meeting®
Nov 2, 2022 06:30AM Lusaris Therapeutics Launches with $60 Million Series A Financing to Redefine the Treatment of Severe Neuropsychiatric and Neurological Disorders
Nov 1, 2022 08:00AM Avilar Therapeutics to Present In Vivo Non-Human Primate Data on ASGPR-Targeting Chimeras (ATACs) at the Keystone Symposium on Targeted Protein Degradation
Oct 24, 2022 04:43PM Form SC 13G IMARA Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Oct 24, 2022 08:00AM Ocelot Bio to Present Data Highlighting Pharmacodynamic Activity and Safety of OCE-205 at AASLD The Liver Meeting®
Oct 21, 2022 06:05AM Form SC 13D/A 89bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Oct 19, 2022 04:37PM Form SC 13D/A DICE Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Oct 18, 2022 08:00AM Avilar Therapeutics to Present New In Vivo Proof-of-Concept Data for ATAC Extracellular Protein Degraders at Upcoming Drug Discovery Conferences
Oct 18, 2022 08:00AM LENZ Therapeutics Announces Positive Topline Data from Phase 2 INSIGHT Trial of LNZ100 and LNZ101 to Treat Presbyopia
Oct 17, 2022 05:22PM Form SC 13G Inhibrx, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Oct 17, 2022 04:32PM Form SC 13G Adicet Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Oct 14, 2022 04:05PM Form SC 13D/A Forma Therapeutics Holdi Filed by: RA CAPITAL MANAGEMENT, L.P.
Oct 13, 2022 04:38PM Imara Inc. (IMRA) to Combine with Enliven Therapeutics in All-Stock Transaction
Oct 13, 2022 04:35PM Enliven Therapeutics and Imara Announce Merger Agreement
Oct 13, 2022 04:35PM Enliven Therapeutics and Imara Announce Merger Agreement
Oct 13, 2022 04:30PM Form SC 13G Design Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Oct 11, 2022 11:06AM GentiBio Announces Preclinical Data Showing Antigen Specific Engineered Tregs Suppressing Pancreatic Inflammation and Potential Utility for Treatment and Prevention of Clinical Type 1 Diabetes (T1D)
Oct 4, 2022 05:15PM Form SC 13D/A Solid Biosciences Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Oct 3, 2022 04:31PM Form SC 13G ALPINE IMMUNE SCIENCES, Filed by: RA CAPITAL MANAGEMENT, L.P.
Sep 30, 2022 07:01AM Solid Biosciences (SLDB) Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement
Sep 30, 2022 07:00AM Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement
Sep 29, 2022 04:00PM Scribe Therapeutics to Participate in Upcoming Investor Conferences
Sep 27, 2022 10:41AM Form SC 13G/A Magenta Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Sep 27, 2022 07:00AM Scribe Therapeutics Announces Research Collaboration with Sanofi to Accelerate Breakthrough CRISPR-based Cell Therapies for Cancer
Sep 26, 2022 05:29PM Form SC 13D/A POINT Biopharma Global Filed by: RA CAPITAL MANAGEMENT, L.P.
Sep 26, 2022 04:38PM Form SC 13G Magenta Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Sep 26, 2022 04:30PM Form SC 13G Third Harmonic Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Sep 22, 2022 08:00AM PepGen Appoints Habib Dable to Board of Directors
Sep 22, 2022 08:00AM PepGen Appoints Habib Dable to Board of Directors
Sep 22, 2022 07:00AM Rivus Pharmaceuticals Closes $132 Million Series B Financing to Advance HU6 for the Treatment of Obesity and Cardio-Metabolic Disorders
Sep 21, 2022 08:31AM Latham BioPharm Group Announces Publication of Team Member's Paper in Leading Scientific Journal
Sep 16, 2022 04:30PM Form SC 13D/A POINT Biopharma Global Filed by: RA CAPITAL MANAGEMENT, L.P.
Sep 14, 2022 09:00AM GentiBio To Present Preclinical Data Demonstrating Technical Progress to Engineer Regulatory T Cells for the Prevention and Treatment of Autoimmune Diseases
Sep 12, 2022 07:00AM Nimbus Therapeutics Closes $125M Private Financing to Advance Clinical Programs in Autoimmune Diseases and Oncology
Sep 6, 2022 04:50PM Form SC 13D/A Solid Biosciences Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Sep 6, 2022 04:31PM Form SC 13G Cogent Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Sep 2, 2022 04:30PM Form SC 13D/A Forma Therapeutics Holdi Filed by: RA CAPITAL MANAGEMENT, L.P.
Sep 1, 2022 08:01AM Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
Sep 1, 2022 08:01AM Forma Therapeutics (FMTX) Acquired by Novo Nordisk for $20/sh or $1.1B
Sep 1, 2022 08:00AM Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
Aug 29, 2022 05:02PM Form SC 13D/A POINT Biopharma Global Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 26, 2022 04:39PM Form SC 13G Fulcrum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 22, 2022 08:30AM Ocelot Bio Receives FDA Orphan Drug Designation for OCE-205 for the Treatment of Hepatorenal Syndrome
Aug 22, 2022 07:00AM Concert Pharmaceuticals Announces Exercise of Warrants Under Existing Financing Arrangement
Aug 15, 2022 05:24PM Form 13F-HR RA CAPITAL MANAGEMENT, For: Jun 30
Aug 15, 2022 05:20PM Form SC 13G/A scPharmaceuticals Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 15, 2022 05:15PM Form SC 13G/A MACROGENICS INC Filed by: RA CAPITAL MANAGEMENT, L.P.
View More Recent Stories View Older Stories